No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
HK Stock MarketDetailed Quotes
01349 FUDANZHANGJIANG
- 2.480
- +0.100+4.20%
Market Closed Feb 14 16:08 CST
2.57BMarket Cap21.95P/E (TTM)
2.490High2.380Low3.58MVolume2.380Open2.380Pre Close8.78MTurnover1.10%Turnover Ratio21.38P/E (Static)1.04BShares4.42052wk High0.99P/B808.48MFloat Cap1.66352wk Low0.10Dividend TTM326.00MShs Float11.965Historical High0.076Dividend LFY4.62%Amplitude-0.575Historical Low2.453Avg Price1000Lot Size3.91%Div YieldTTM3.06%Div Yield LFY
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Warning: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) expects an increase in research and development expenses, projecting a decrease in annual profits by 52%-68%.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) issued a profit warning, forecasting that the net profit attributable to the parent company for the fiscal year 2024 will be between 35 million and 52 million yuan, a decrease of 52.1%-67.8% compared to the previous year. The reason is that the group is actively promoting the progress of R&D projects, with R&D expenses increasing by approximately 70 million yuan.
Fudan Zhangjiang 2024 Annual Results Forecast Announcement
Fudan-Zhangjiang Bio-Pharma Expects Up to 68% Lower Net Profit in 2024
FUDANZHANGJIANG: INSIDE INFORMATION / PROFIT WARNING
Express News | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. expects its net income to decrease by 52.13% to 67.78% year-on-year in 2024.
Trending Stocks
HK Dividend Stocks HK Dividend Stocks
Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data. Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data.
Log In for the Full List
Unlock Now
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha